VRDN

Viridian Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$30.48

Price (1 Year)

$33.26 $13.42

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %22.9 / %30
Non-compliant assets / Total market cap %58.1 / %30
Non-compliant revenue / Total income %56.7 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.

Website

Analysis (Turkish): VRDN Hissesi Caiz mi, Helal mi? Viridian Therapeutics, Inc. Katılım Analizi